Bicara Therapeutics BCAX Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Bicara Therapeutics (BCAX) reported debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss of $245K in Q1 2026.